Non Hodgkin Lymphoma Clinical Trial

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

View Full Description

Full Description

Participants with relapsed or refractory non-Hodgkin's lymphomas (R/R NHL) who have failed at least 2 lines of therapy (or have received at least one prior line of standard therapy and are not eligible for any other therapy).

The dose escalation will evaluate the safety and tolerability of escalating doses of CC-99282 in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and/or relapsed or refractory follicular lymphoma (R/R FL) participants to determine the maximum tolerated dose (MTD) of CC-99282 as monotherapy.

The dose expansion will further evaluate the safety and preliminary efficacy of single agent CC-99282 administered at or below MTD in subjects with R/R DLBCL and NHL. Part B will also evaluate the safety and preliminary efficacy of CC-99282 in combination with anti-lymphoma agents in participants with R/R DLBCL and R/R FL.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

Exclusion Criteria:

Life expectancy ≤ 2 months
Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter
Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD)
Impaired cardiac function or clinically significant cardiac disease

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

210

Study ID:

NCT03930953

Recruitment Status:

Recruiting

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 58 Locations for this study

See Locations Near You

Local Institution - 114
Los Angeles California, 90048, United States More Info
Site 114
Contact
University of California, Irvine
Orange California, 92848, United States
University of California, Irvine
Orange California, 92848, United States
Oncology Institute of Hope and Innovation
Whittier California, 90603, United States More Info
Amitabha Mazumder, Site 112
Contact
562-693-4477
H Lee Moffitt Cancer Center
Tampa Florida, 32207, United States
H Lee Moffitt Cancer Center
Tampa Florida, 32207, United States More Info
Julio Chavez, Site 102
Contact
813-745-3875
University Of Kansas Cancer Center
Overland Park Kansas, 66210, United States
University Of Maryland At Baltimore
Baltimore Maryland, 21201, United States More Info
Seung Tae Lee, Site 113
Contact
Mayo Clinic in Rochester, Minnesota
Rochester Minnesota, 55905, United States
Washington University
Saint Louis Missouri, 63110, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Perlmutter Cancer Center at NYU Langone Hospital-Long Island
Mineola New York, 11501, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Loretta Nastoupil, Site 101
Contact
713-745-8145
Local Institution - 251
Ciudad autónoma de Buenos Aires Buenos Aires, 1280, Argentina More Info
Site 251
Contact
Local Institution - 250
Buenos Aires , C1426, Argentina More Info
Site 250
Contact
Local Institution - 252
Cordoba , 5016, Argentina More Info
Site 252
Contact
LKH - Universitätsklinikum der PMU Salzburg
Salzburg , 5020, Austria
Local Institution - 704
Sankt Pölten , 3100, Austria More Info
Site 704
Contact
Universitätsklinikum St. Pölten
Sankt Pölten , 3100, Austria
Local Institution - 703
Vienna , 1090, Austria More Info
Site 703
Contact
Medical University Vienna
Vienna , 1090, Austria
UZ Antwerpen
Edegem , 2650, Belgium
UZ Leuven
Leuven , 3000, Belgium
Cross Cancer Institute University of Alberta
Edmonton Alberta, T6G1Z, Canada
Princess Margaret Cancer Centre
Toronto Ontario, M5G 2, Canada
McGill University Health Centre MUHC
Montreal , H3H 2, Canada
Local Institution - 353
Santiago Metropolitana, 75009, Chile More Info
Site 353
Contact
Local Institution - 352
Santiago Metropolitana, 83200, Chile More Info
Site 352
Contact
Local Institution - 350
Las Condes Santiago De Chile, 75609, Chile More Info
Site 350
Contact
Local Institution - 0909
Santiago , 75910, Chile
Local Institution - 351
Santiago , 838-0, Chile More Info
Site 351
Contact
Aarhus University Hospital
Aarhus C , DK-80, Denmark
Local Institution - 602
Aarhus , 8200, Denmark More Info
Site 602
Contact
Rigshospitalet University Hospital
Copenhagen , 2100, Denmark
Local Institution - 603
Vejle , 7100, Denmark More Info
Site 603
Contact
Vejle Hospital
Vejle , 7100, Denmark
Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
Bordeaux , 33076, France
Local Institution - 407
Bordeaux , 33076, France More Info
Site 407
Contact
Hopital Henri Mondor
Creteil , 94010, France
Local Institution - 403
Creteil , 94010, France More Info
Site 403
Contact
CHRU de Lille - Hopital Claude Huriez
Lillie Cedex , 59037, France
Local Institution - 406
Lillie Cedex , 59037, France More Info
Site 406
Contact
Local Institution - 0904
Montpellier CEDEX 5 , 34295, France
Local Institution - 409
Montpellier CEDEX 5 , 34295, France More Info
Site 409
Contact
Hopital Saint-Louis
Paris , 75010, France More Info
Catherine Thieblemont, Site 405
Contact
33142499236
Centre Hospitalier Lyon-Sud
Pierre-Benite CEDEX , 69495, France
Centre Henri Becquerel
Rouen , 76038, France
Institut Claudius Regaud, IUCT-Oncopole
Toulouse , 31059, France
Local Institution - 408
Toulouse , 31059, France More Info
Site 408
Contact
Gustave Roussy
Villejuif CEDEX , 94805, France
Local Institution - 401
Villejuif CEDEX , 94805, France More Info
Site 401
Contact
Local Institution - 150
Jerusalem , 91120, Israel More Info
Site 150
Contact
Local Institution - 151
Petah Tikva , 49100, Israel More Info
Site 151
Contact
Local Institution - 152
Ramat Gan , 52621, Israel More Info
Site 152
Contact
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo , 24127, Italy
Local Institution - 501
Bergamo , 24127, Italy More Info
Site 501
Contact
Local Institution - 504
Bologna , 40138, Italy More Info
Site 504
Contact
ASST Grande Ospedale Metropolitano Niguarda, Milano
Milano , 20162, Italy
Local Institution - 503
Milano , 20162, Italy More Info
Site 503
Contact
Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale"
Napoli , 80131, Italy
Local Institution - 505
Rozzano , 20089, Italy More Info
Site 505
Contact
Hospital Universitari Germans Trias i Pujol Can Ruti
Badalona (Barcelona) , 08916, Spain
Local Institution - 306
Badalona (Barcelona) , 08916, Spain More Info
Site 306
Contact
Local Institution - 301
Barcelona , 08035, Spain More Info
Site 301
Contact
Vall d´Hebron University Hospital
Barcelona , 08035, Spain
Fundacion Jimenez Daaz
Madrid , 28040, Spain
Hospital La Paz
Madrid , 28046, Spain
Local Institution - 304
Madrid , 28046, Spain More Info
Site 304
Contact
Hospital Universitario Virgen De La Victoria
Malaga , 29010, Spain
Local Institution - 303
Malaga , 29010, Spain More Info
Site 303
Contact
Hospital Universitario de Salamanca
Salamanca , 37007, Spain
Local Institution - 0905
Belfast Northern Ireland , BT9 7, United Kingdom
Local Institution - 802
Edinburgh Scotland , EH4 2, United Kingdom More Info
Site 802
Contact
Western General Hospital
Edinburgh Scotland , EH4 2, United Kingdom
University College London Hospitals NHS Foundation Trust - University College Hospital
London , NW1 2, United Kingdom
Southampton General Hospital
Southhampton , SO01 , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

210

Study ID:

NCT03930953

Recruitment Status:

Recruiting

Sponsor:


Celgene

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.